Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Blockade of the epidermal growth factor receptor (EGFR) with cetuximab or panitumumab monoclonal antibodies is effective in a subset of colorectal cancers (CRCs), but the efficacy of these therapeutic agents can be limited due to the emergence of resistances. At relapse, the majority of patients develop RAS mutations, while a subset acquires EGFR extracellular domain […]
